Fecal Microbiota Transplantation (FMT) & Acute myeloid leukemia (AML) (therapy-associated infections)

Fecal Microbiota Transplantation (FMT) is being studied for Acute myeloid leukemia (AML) (associated infections). It aims to restore the microbiome after chemotherapy and antibiotics. The goals are to reduce dysbiosis and infections. It may also help with treatment complications. Clinical data shows FMT is feasible and safe in trials. It helps with microbiota recovery. However, it hasn't clearly reduced infection rates in randomized tests yet (1, 2, 3)

Randomized clinical trials (RCTs)

NCT03678493
FMT did not reduce infections (2)

XXX(1) - Fecal Microbiota Transplantation (FMT) & Acute myeloid leukemia (AML) (therapy-associated infections) (1)
No published results were found as of May 2026

References

(1) Ebadi et al. 2021 J Clin Transl Sci 5(Suppl_1): 36
(2) Rashidi et al. 2023 Journal of Clinical Oncology 41(34): 5306-5319
(3) Mothy et al. 2017 Blood blood 130(Suppl_1): 2624

see also:
Acute myeloid leukemia (AML) (therapy-associated infections) & Drugs/Treatments
Microbiome-based therapeutics & Acute myeloid leukemia (AML) (therapy-associated infections)